The Relationship Between Odontogenic Cyst and P53 Codon 72 And P53 Codon 175 Variants in Turkish Patients
Abstract views: 174 / PDF downloads: 109
DOI:
https://doi.org/10.58600/eurjther1911Keywords:
odontogenic cyst, Gene, MetaplasiaAbstract
Objective: Odontogenic cysts that cause bone destruction can exhibit various types of metaplasia. Inherited genetic variants in codons 72 and 175, the hotspot codons of p53, known as the guardian of the genome, can cause a wide variety of cancers. We aimed to investigate the effects of the p53 codon 72 and p53 codon 175 variants on odontogenic cyst formation.
Methods: This research encompassed 71 individuals with odontogenic cysts and 90 without any conditions as a control group. After DNA was extracting, the p53 codon 72 was detected using PCR techniques, while p53 codon 175 was identified through allele-specific amplification-PCR.
Results: The presence of the p53 codon 72 GG genotype and its G allele was less frequent in the group with odontogenic cysts compared to the healthy participants. Conversely, the C allele was found more often in the cyst-afflicted group. For the p53 codon 175, the AA genotype and A allele were more common in the affected group, while the G allele was more predominant in the control group.
Conclusion: The p53 codon 175 AA genotype and A allele, p53 codon 72 C allele, and p53 codon 72/codon 175 CCAA combined genotype may be associated with odontagenic cyst formation. Individuals with this allele and genotype can be considered at risk for odontagenic cyst formation.
Metrics
References
Rajendra Santosh AB (2020) Odontogenic Cysts. Dent Clin North Am 64(1):105-119. https://doi.org/10.1016/j.cden.2019.08.002
Manjunatha BS, Das N, Ahmed T (2018) Odontogenic cyst with diverse histopathological features: report of an unusual case. J Exp Ther Oncol. 12(4):295-302. PMID: 30476385
Sabapathy K, Lane DP (2019) Understanding p53 functions through p53 antibodies. J Mol Cell Biol. 11(4):317-329. https://doi.org/10.1093/jmcb/mjz010
Kanapathipillai M (2018) Treating p53 Mutant Aggregation-Associated Cancer. Cancers (Basel).10(6):154. https://doi.org/10.3390/cancers10060154
Vietri MT, Molinari AM, Iannella I, Cioffi M, Bontempo P, Ardovino M, Scaffa C, Colacurci N, Cobellis L (2007) Arg72Pro p53 polymorphism in Italian women: no association with endometriosis. Fertil Steril. 88(5):1468-9. https://doi.org/10.1016/j.fertnstert.2006.12.049
Yi K, Yang L, Lan Z, Xi M (2016) The Association Between p53 Codon 72 Polymorphism and Endometrial Cancer Risk: A System Review and Meta-analysis. Int J Gynecol Cancer. 26(6):1121-1128. https://doi.org/10.1097/IGC.0000000000000725
Kim BY, Lee SY, Chung SK (2021) Differential Transcriptional Regulation of Polymorphic p53 Codon 72 in Metabolic Pathways. Int J Mol Sci. 22(19):10793. https://doi.org/10.3390/ijms221910793
Rahmé R, Braun T, Manfredi JJ, Fenaux P (2023) TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia. Biomedicines. 11(4):1152. https://doi.org/10.1111/cen.14864
Heinsohn S, Scholz R, Kabisch H (2011) SV40 and p53 as team players in childhood lymphoproliferative disorders. Int J Oncol. 38(5):1307-1317. https://doi.org/10.3892/ijo.2011.967
Srividya, Giridhar BH, Vishwanath S, Chakraborty A (2019) Profiling of Germline Mutations in Major Hotspot Codons of TP53 Using PCR-RFLP. Pathol Oncol Res. 25(4):1373-1377. https://doi.org/10.1007/s12253-018-0394-8
Stracquadanio G, Wang X, Wallace MD, Grawenda AM, Zhang P, Hewitt J, Zeron-Medina J, Castro-Giner F, Tomlinson IP, Goding CR, Cygan KJ, Fairbrother WG, Thomas LF, Sætrom P, Gemignani F, Landi S, Schuster-Böckler B, Bell DA, Bond GL (2016) The importance of p53 pathway genetics in inherited and somatic cancer genomes. Nat Rev Cancer. 16(4):251-265. https://doi.org/10.1038/nrc.2016.15
Hrstka R, Coates PJ, Vojtesek B (2009) Polymorphisms in p53 and the p53 pathway, roles in cancer susceptibility and response to treatment. J Cell Mol Med. 13(3):440-453. https://doi.org/10.1111/j.1582-4934.2008.00634.x
Zhou C, Chen H, Wang A (2013) P53 codon 72 polymorphism and lung cancer risk, evidence from 27,958 subjects. Tumour Biol. 34(5):2961-2969. https://doi.org/10.1007/s13277-013-0859-z
Chen FM, Ou-Yang F, Yang SF, Tsai EM, Hou MF (2013) P53 codon 72 polymorphism in Taiwanese breast cancer patients. Kaohsiung J Med Sci. 29(5):259-264. https://doi.org/10.1016/j.kjms.2012.09.004
He F, Xia Y, Liu H, Li J, Wang C (2013) P53 codon 72 Arg/Pro polymorphism and glioma risk: an updated meta-analysis. Tumour Biol. 34(5):3121-3130. https://doi.org/10.1007/s13277-013-0880-2
Hou J, Gu Y, Hou W, Wu S, Lou Y, Yang W, Zhu L, Hu Y, Sun M, Xue H (2015) P53 codon 72 polymorphism, human papillomavirus infection, and their interaction to oral carcinoma susceptibility. BMC Genet. 16:72. https://doi.org/10.1186/s12863-015-0235-7
Bau DT, Tsai MH, Lo YL, Hsu CM, Tsai Y, Lee CC, Tsai FJ (2007) Association of p53 and p21(CDKN1A/WAF1/CIP1) polymorphisms with oral cancer in Taiwan patients. Anticancer Res. 27(3B):1559-1564.
Sina M, Pedram M, Ghojazadeh M, Kochaki A, Aghbali A (2014) P53 gene codon 72 polymorphism in patients with oral squamous cell carcinoma in the population of northern Iran. Med Oral Patol Oral Cir Bucal. 19(6):e550-555. https://doi.org/10.4317/medoral.19794
Twu CW, Jiang RS, Shu CH, Lin JC (2006) Association of p53 codon 72 polymorphism with risk of hypopharyngeal squamous cell carcinoma in Taiwan. J Formos Med Assoc. 105(2):99-104. https://doi.org/10.1016/S0929-6646(09)60330-2
Yanatatsaneejit P, Boonsrang A, Mutirangura A, Patel V, Kitkumthorn N (2015) P53 polymorphism at codon 72 is associated with keratocystic odontogenic tumors in the Thai population. Asian Pac J Cancer Prev. 16(5):1997-2001. https://doi.org/10.7314/apjcp.2015.16.5.1997
Kitkumthorn N, Yanatatsaneejit P, Rabalert J, Dhammawipark C, Mutirangura A (2010) Association of P53 codon 72 polymorphism and ameloblastoma. Oral Dis. 16(7):631-635. https://doi.org/10.1111/j.1601-0825.2010.01664.x
Krajewska WM, Stawińska M, Bryś M, Młynarski W, Witas HW, Okruszek A, Kiliańska ZM (2003) Genotyping of p53 codon 175 in colorectal cancer. Med Sci Monit. 9(5):188-191.
England B, Huang T, Karsy M (2013) Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme. Tumour Biol. 34(4):2063-2074. https://doi.org/10.1007/s13277-013-0871-3
Downloads
Published
How to Cite
License
Copyright (c) 2023 European Journal of Therapeutics
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.